LAGUNA HILLS, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today announced that its research partner, the University of Northern Colorado (UNC), has submitted abstracts for the presentation of two scientific papers at the 253rd American Chemical Society (ACS) National Meeting & Exposition in San Francisco, California, April 2-6, 2017. The ACS National Meeting provides chemistry professionals a forum to meet, share ideas and advance scientific and technical knowledge. The theme of the upcoming meeting is "Advanced Materials, Technologies, Systems & Processes." PharmaCyte's Cannabis research at UNC fits the theme perfectly since it revolves around utilization of PharmaCyte's proprietary Cell-in-a-Box ® technology. The papers will be presented by Dr. Richard M. Hyslop, Principal Investigator and Professor of Chemistry and Biochemistry at UNC and his students. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, commented "We are very pleased with the ongoing progress at UNC. The upcoming ACS meeting provides an ideal venue to present two more scientific papers that have been generated from the work being done by Dr. Hyslop and his team as well as showcase the versatility of Cell-in-a-Box ® as an advanced therapeutic platform." The first paper is titled "Development of a cannabinoid-based Cell-in-a-Box ® therapeutic system targeted toward malignant tumors." This aspect of the UNC research investigates the feasibility of a patented cell-encapsulation technology in which cells producing enzymes capable of converting an inactive phytocannabinoid prodrug into an active anti-cancer drug are encapsulated in a cellulose-based porous polymer, which can be injected immediately upstream from a tumor. Then, an administered phytocannabinoid prodrug can be activated by the encapsulated cells at the site of the tumor. The paper describes how, using both specific phytocannabinoids and model compounds, a variety of cell lines have been screened for the appropriate enzymatic activity to convert an inactive cannabinoid prodrug into an active drug. Five cell lines have been observed to produce the desired enzyme and are being further assessed with specific phytocannabinoid prodrugs.